Leukotriene Antagonist Clinical Trials

• Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial
  ClinicalTrials.gov Identifier: NCT00046644 - Active, not recruiting
  Asthma; Lung Diseases
  
• Leukotriene Receptor Antagonists or Steroids in Pre-School Asthma
  ClinicalTrials.gov Identifier: NCT00543686 - Recruiting
  Asthma
  
• The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial (The LOCCS Trial)
  ClinicalTrials.gov Identifier: NCT00156819 - Active, not recruiting
  Asthma
  
• Trial of Aldosterone Antagonist Therapy in Adults with Preserved Ejection Fraction Congestive Heart Failure (TOPCAT)
  ClinicalTrials.gov Identifier: NCT00094302 - Recruiting
  Cardiovascular Diseases; Heart Diseases; Heart Failure
  
• MASCOT: Mixed Antagonist of Serotonin for Claudication Optimal Therapy
  ClinicalTrials.gov Identifier: NCT00300339 - Active, not recruiting
  Intermittent Claudication
  
• Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder
  ClinicalTrials.gov Identifier: NCT00383786 - Recruiting
  PTSD
  
• GnRH Antagonist to Prepare Recipients for Embryo Transfer
  ClinicalTrials.gov Identifier: NCT00460642 - Recruiting
  Infertility
  
• Treatment of Uterine Fibroids with CDB-2914, an Experimental Selective Progesterone Receptor Antagonist
  ClinicalTrials.gov Identifier: NCT00044876 - Active, not recruiting
  Leiomyoma
  
• A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bronchial Responsiveness To Leukotriene D4 In Asthmatics Patients
  ClinicalTrials.gov Identifier: NCT00453778 - Completed
  Mild Asthma
  
• Gonadotropin-Releasing Hormone Antagonist on Triggering Day: A Randomized Controlled Study
  ClinicalTrials.gov Identifier: NCT00571870 - Recruiting
  Infertility
  
• Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy
  ClinicalTrials.gov Identifier: NCT00452283 - Recruiting
  Glaucoma; Pulmonary Hypertension
  
• The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function
  ClinicalTrials.gov Identifier: NCT00526968 - Recruiting
  Human Volunteers
  
• Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
  ClinicalTrials.gov Identifier: NCT00049296 - Active, not recruiting
  Cancer
  
• Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
  ClinicalTrials.gov Identifier: NCT00339157 - Active, not recruiting
  Systemic-Onset Juvenile Idiopathic Arthritis
  
• SU5416 in Treating Children With Recurrent or Progressive Brain Tumors
  ClinicalTrials.gov Identifier: NCT00006247 - Active, not recruiting
  Brain Cancer
  
• Thalidomide in Treating Patients With Myelofibrosis
  ClinicalTrials.gov Identifier: NCT00015821 - Active, not recruiting
  Agnogenic Myeloid Metaplasia
  
• Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00082823 - Active, not recruiting
  Cancer
  
• Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00083213 - Active, not recruiting
  Cancer
  
• Enzastaurin in Treating Patients With Recurrent Gliomas
  ClinicalTrials.gov Identifier: NCT00112788 - Active, not recruiting
  adult brain tumor
  
• Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00182689 - Active, not recruiting
  Lung Cancer
  
• AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00022282 - Active, not recruiting
  refractory plasma cell neoplasm
  
• Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors
  ClinicalTrials.gov Identifier: NCT00471588 - Recruiting
  Obsessive-Compulsive Disorder
  
• Efficacy and Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combination With Ondansetron and Dexamethasone in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation
  ClinicalTrials.gov Identifier: NCT00314743 - Recruiting
  Nausea; Vomiting
  
• Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00052416 - Active, not recruiting
  adult non-Hodgkin's lymphoma
  
• FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
  ClinicalTrials.gov Identifier: NCT00104884 - Active, not recruiting
  intraocular melanoma; Melanoma
  
• Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
  ClinicalTrials.gov Identifier: NCT00033254 - Active, not recruiting
  brain metastases
  
• Sorafenib in Treating Patients with Stage IV Melanoma
  ClinicalTrials.gov Identifier: NCT00119249 - Active, not recruiting
  Stage IV Melanoma
  
• Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
  ClinicalTrials.gov Identifier: NCT00217620 - Active, not recruiting
  adult soft tissue sarcoma
  
• Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
  ClinicalTrials.gov Identifier: NCT00025220 - Active, not recruiting
  recurrent uterine sarcoma; uterine leiomyosarcoma
  
• Tipifarnib in Treating Patients With Metastatic Malignant Melanoma
  ClinicalTrials.gov Identifier: NCT00060125 - Active, not recruiting
  Stage IV Melanoma; Recurrent Melanoma
  
• Oral Neurokinin-1 Antagonist, Aprepitant, in Combination With Ondansetron and Dexamethasone in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation
  ClinicalTrials.gov Identifier: NCT00285272 - Recruiting
  Chemotherapy Induced Nausea and Vomiting; Non-Hodgkins Lymphoma; Multiple Myeloma
  
• Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00003644 - Active, not recruiting
  ovarian epithelial cancer
  
• Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00016224 - Active, not recruiting
  recurrent ovarian epithelial cancer
  
• Celecoxib in Treating Patients With Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00006124 - Active, not recruiting
  recurrent bladder cancer
  
• PEKASYS- Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis
  ClinicalTrials.gov Identifier: NCT00332904 - Recruiting
  Liver Cirrhosis; Portal Hypertension
  
• A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
  ClinicalTrials.gov Identifier: NCT00554229 - Recruiting
  Prostate Cancer
  
• Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation
  ClinicalTrials.gov Identifier: NCT00417183 - Recruiting
  Infertility
  
• Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00104988 - Active, not recruiting
  Stage IV Melanoma
  
• Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00547612 - Recruiting
  Pancreatic Cancer
  
• PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
  ClinicalTrials.gov Identifier: NCT00328692 - Recruiting
  Heart Failure, Congestive
  
• PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
  ClinicalTrials.gov Identifier: NCT00354458 - Recruiting
  Heart Failure, Congestive
  
• Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00096512 - Active, not recruiting
  Head and Neck Cancer
  
• Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
  ClinicalTrials.gov Identifier: NCT00005815 - Active, not recruiting
  intraocular melanoma; Melanoma
  
• Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
  ClinicalTrials.gov Identifier: NCT00072345 - Active, not recruiting
  intraocular melanoma; Melanoma
  
• Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma
  ClinicalTrials.gov Identifier: NCT00082875 - Active, not recruiting
  stage III melanoma; Stage IV Melanoma
  
• Chemotherapy in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00003721 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• S-3304 in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00033566 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• SU5416 in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00005642 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
  ClinicalTrials.gov Identifier: NCT00325442 - Recruiting
  Pulmonary Hypertension
  
• Everolimus in Treating Patients With Stage IV Melanoma
  ClinicalTrials.gov Identifier: NCT00098553 - Active, not recruiting
  Stage IV Melanoma; Recurrent Melanoma
  
• COL-3 in Treating Patients With HIV-Related Kaposi's Sarcoma
  ClinicalTrials.gov Identifier: NCT00020683 - Active, not recruiting
  epidemic Kaposi's sarcoma; recurrent Kaposi's sarcoma
  
• LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00052273 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers
  ClinicalTrials.gov Identifier: NCT00020878 - Active, not recruiting
  Non-small cell lung cancer
  
• Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00027677 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Topical Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma
  ClinicalTrials.gov Identifier: NCT00064142 - Active, not recruiting
  epidemic Kaposi's sarcoma; recurrent Kaposi's sarcoma
  
• Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00049374 - Active, not recruiting
  refractory plasma cell neoplasm
  
• CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
  ClinicalTrials.gov Identifier: NCT00031941 - Active, not recruiting
  adult solid tumor; Leukemia; Lymphoma; small intestine cancer
  
• Cilengitide in Treating Patients With Metastatic Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00103337 - Active, not recruiting
  recurrent prostate cancer; stage IV prostate cancer
  
• GW786034 in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00060151 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00058006 - Active, not recruiting
  Head and Neck Cancer; thorax and respiratory cancer
  
• Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
  ClinicalTrials.gov Identifier: NCT00112671 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter
  
• Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
  ClinicalTrials.gov Identifier: NCT00045591 - Active, not recruiting
  recurrent breast cancer; stage IV breast cancer
  
• Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients
  ClinicalTrials.gov Identifier: NCT00417144 - Recruiting
  Polycystic Ovary Syndrome; Ovarian Hyperstimulation Syndrome
  
• ZD6474 and Docetaxel in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00054093 - Active, not recruiting
  Non-small cell lung cancer
  
• Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
  ClinicalTrials.gov Identifier: NCT00027638 - Active, not recruiting
  gastrointestinal carcinoid tumor; Islet Cell Carcinoma; pulmonary carcinoid tumor
  
• VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00045266 - Active, not recruiting
  adult non-Hodgkin's lymphoma; adult solid tumor
  
• Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
  ClinicalTrials.gov Identifier: NCT00552851 - Recruiting
  Acromegaly; Heart Failure; Hypertrophy, Left Ventricular
  
• SU011248 in Treating Women With Metastatic Breast Cancer That Did Not Respond to Anthracycline or Taxane Chemotherapy
  ClinicalTrials.gov Identifier: NCT00095615 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Sorafenib in Treating Patients With Recurrent Diffuse Large B-Cell Non-Hodgkin''s Lymphoma
  ClinicalTrials.gov Identifier: NCT00131937 - Active, not recruiting
  recurrent adult diffuse large cell lymphoma
  
• Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00006226 - Active, not recruiting
  refractory chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia
  
• Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00091299 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
  ClinicalTrials.gov Identifier: NCT00033709 - Active, not recruiting
  adult soft tissue sarcoma; uterine leiomyosarcoma; uterine sarcoma
  
• Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
  ClinicalTrials.gov Identifier: NCT00060242 - Active, not recruiting
  anaplastic thyroid cancer; recurrent thyroid cancer
  
• Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00068653 - Active, not recruiting
  recurrent non-small cell lung cancer
  
• Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
  ClinicalTrials.gov Identifier: NCT00028678 - Active, not recruiting
  adult glioblastoma; adult giant cell glioblastoma; adult gliosarcoma
  
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00055913 - Active, not recruiting
  Head and Neck Cancer
  
• Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
  ClinicalTrials.gov Identifier: NCT00025233 - Active, not recruiting
  recurrent cervical cancer; cervical squamous cell carcinoma
  
• In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer
  ClinicalTrials.gov Identifier: NCT00086723 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Cilengitide in Treating Children With Refractory Primary Brain Tumors
  ClinicalTrials.gov Identifier: NCT00063973 - Active, not recruiting
  childhood brain tumor; childhood meningioma; childhood spinal cord tumors
  
• PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
  ClinicalTrials.gov Identifier: NCT00053885 - Active, not recruiting
  advanced malignant mesothelioma; epithelial mesothelioma; recurrent malignant mesothelioma; sarcomatous mesothelioma
  
• Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00255762 - Active, not recruiting
  Recurrent Melanoma; Stage IV Melanoma
  
• Sorafenib in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00096434 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer; Male Breast Cancer
  
• Sorafenib in Treating Patients With Malignant Mesothelioma
  ClinicalTrials.gov Identifier: NCT00107432 - Active, not recruiting
  advanced malignant mesothelioma; epithelial mesothelioma; recurrent malignant mesothelioma; sarcomatous mesothelioma
  
• Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00093626 - Active, not recruiting
  recurrent ovarian epithelial cancer; peritoneal cavity cancer
  
• Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00053300 - Active, not recruiting
  extensive stage small cell lung cancer
  
• Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT
  ClinicalTrials.gov Identifier: NCT00021931 - Completed
  Asthma; Lung Diseases
  
• Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00031837 - Active, not recruiting
  adenocarcinoma of the pancreas; Pancreatic Cancer; Quality of Life; Thromboembolism
  
• Sorafenib and Gemcitabine in Treating Patients With Recurrent or Refractory Ovarian Cancer or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00096395 - Active, not recruiting
  peritoneal cavity cancer; recurrent ovarian epithelial cancer
  
• Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00012272 - Active, not recruiting
  Stage IV rectal cancer; stage IV colon cancer
  
• PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00045279 - Active, not recruiting
  Stage IV Renal Cell Cancer
  
• Chemotherapy With or Without Monoclonal Antibody in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00012285 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00083031 - Active, not recruiting
  recurrent breast cancer; stage IV breast cancer
  
• MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
  ClinicalTrials.gov Identifier: NCT00098891 - Active, not recruiting
  adult solid tumor; Leukemia; Lymphoma; small intestine cancer
  
• Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/neu-Expressing Cancer
  ClinicalTrials.gov Identifier: NCT00084513 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00039104 - Active, not recruiting
  adenocarcinoma of the prostate; stage IV prostate cancer; recurrent prostate cancer
  
• Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
  ClinicalTrials.gov Identifier: NCT00046826 - Active, not recruiting
  adenocarcinoma of the prostate; stage IV prostate cancer; recurrent prostate cancer
  
• AZD2171 in Treating Patients With Progressive Locally Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00227760 - Active, not recruiting
  Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer
  
• SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
  ClinicalTrials.gov Identifier: NCT00006361 - Active, not recruiting
  lip and oral cavity cancer; Skin Cancer; Head and Neck Cancer; Oropharyngeal Cancer
  
• Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00012233 - Active, not recruiting
  Stage IV rectal cancer; stage IV colon cancer
  
• Interleukin-12 and Interferon alfa in Treating Patients With Metastatic Malignant Melanoma
  ClinicalTrials.gov Identifier: NCT00026143 - Active, not recruiting
  Stage IV Melanoma; Recurrent Melanoma